Stock listing

NASDAQ:ANAB AnaptysBio, Inc. Stock

Home listing (NASDAQ) of AnaptysBio, Inc.

Follow AnaptysBio, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:ANAB

$46.63 USD -0.43 (-0.9%)

Close on Nov 20, 2026

Past year +85.7% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$46.05 – $47.66 USDNov 20, 2026
Volume
432,444 sharesNov 20, 2026
Market cap
$1.39B USDAt the close on Nov 20, 2026 · price × 29.90M shares outstanding
52-week range
$22.07 – $72.36 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$25.00M USDMedian day 421,700 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
AnaptysBio, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:ANAB · Home$46.63 USD-0.43 (-0.9%)432,444$46.63$47.66$46.05$47.06Close on Nov 20, 2026
LSE:0HFQ$46.91 USD-0.889 (-1.9%)850$45.76$47.32$45.76$47.80Close on Nov 20, 2026
Frankfurt:AN6€41.93 EUR-0.16 (-0.4%)—€42.31€42.44€41.32€42.09Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ANAB · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$46.63-0.43-0.9%$46.63$47.66$46.05432,444
$47.06+1.45+3.2%$45.59$47.18$44.83566,843
$45.61-0.12-0.3%$45.81$46.14$44.99597,690
$45.73-0.52-1.1%$45.78$46.23$44.80483,756
$46.25-1.52-3.2%$45.27$47.36$44.64499,637
$47.77-1.00-2.1%$48.10$48.87$47.68262,895
$48.77+0.39+0.8%$49.00$49.12$47.81230,746
$48.38+0.41+0.9%$47.63$48.66$47.18244,929
$47.97+1.52+3.3%$47.03$48.96$46.19323,838
$46.45+0.87+1.9%$45.85$46.63$45.01287,662
$45.58-1.93-4.1%$47.51$47.74$45.47380,689
$47.51-0.22-0.5%$49.00$49.00$45.82493,423
$47.73+0.82+1.7%$47.36$48.35$47.36304,495
$46.91-1.37-2.8%$48.33$48.37$46.90281,487
$48.28-0.36-0.7%$48.45$48.97$47.89293,615
$48.64-1.86-3.7%$50.61$51.22$48.33414,328
$50.50+0.87+1.8%$49.76$50.55$49.00306,131
$49.63+0.86+1.8%$49.24$50.02$48.70349,577
$48.77+0.04+0.1%$48.97$49.62$47.98417,135
$48.73+0.63+1.3%$48.19$48.89$47.05468,090
$48.10+0.16+0.3%$47.65$48.51$46.83254,904
$47.94+2.51+5.5%$45.48$48.48$45.48664,422
$45.43-3.81-7.7%$49.57$51.85$44.021,201,785
$49.24+2.63+5.6%$47.33$49.88$47.33468,354
$46.61-2.10-4.3%$48.56$48.56$46.46413,600
$48.71+2.04+4.4%$47.43$48.83$46.93416,300
$46.67+1.08+2.4%$45.25$47.24$45.00494,100
$45.59-0.45-1.0%$45.53$46.13$45.16416,500
$46.04+0.09+0.2%$46.16$46.78$45.99371,600
$45.95-0.26-0.6%$46.11$47.19$45.81495,200
$46.21+0.56+1.2%$45.36$46.77$44.74554,200
$45.65-2.24-4.7%$47.00$47.39$45.62766,500
$47.89-1.31-2.7%$49.41$49.41$47.35627,100
$49.20+0.67+1.4%$48.53$49.84$47.52595,500
$48.53-0.10-0.2%$48.97$49.83$48.28441,100
$48.63-1.63-3.2%$49.94$50.98$48.13512,300
$50.26-0.11-0.2%$50.13$52.02$49.391,430,100
$50.37-0.43-0.8%$50.44$50.90$49.46677,600
$50.80-0.20-0.4%$51.00$51.65$50.50412,600
$51.00-0.70-1.4%$52.38$52.38$50.80437,700
$51.70+0.93+1.8%$50.59$52.16$50.35417,800
$50.77-3.15-5.8%$53.55$53.93$49.45779,600
$53.92-1.00-1.8%$55.07$56.04$50.61755,700
$54.92-0.28-0.5%$56.00$56.00$54.09524,400
$55.20+0.14+0.3%$55.76$55.77$53.71868,800
$55.06+0.75+1.4%$55.09$55.79$54.49439,600
$54.31-0.37-0.7%$54.44$54.80$53.62394,100
$54.68+0.57+1.1%$54.28$55.32$53.22351,800
$54.11+0.24+0.4%$54.58$55.70$54.00436,800
$53.87-1.29-2.3%$55.43$56.32$53.75336,200
$55.16-0.54-1.0%$55.43$56.43$54.31300,100
$55.70-0.90-1.6%$55.59$57.89$55.25295,700
$56.60-0.20-0.4%$55.48$58.17$54.791,036,100
$56.80-0.66-1.1%$56.84$58.77$56.101,061,900
$57.46+1.62+2.9%$56.33$57.77$55.00363,800
$55.84+0.56+1.0%$56.13$57.90$54.66421,700
$55.28-1.75-3.1%$56.82$58.09$54.84773,900
$57.03+0.75+1.3%$55.83$57.22$55.00332,100
$56.28-1.01-1.8%$57.24$57.24$55.38358,300
$57.29-0.71-1.2%$58.03$58.43$57.10533,700
$58.00-0.37-0.6%$58.27$58.86$57.37210,300
$58.37-0.07-0.1%$58.09$58.99$56.81341,835
$58.44+0.70+1.2%$56.96$59.07$55.57627,045
$57.74+1.05+1.9%$57.23$58.78$56.62318,400
$56.69-2.57-4.3%$58.52$59.69$56.33389,300

Splits

1 split · NASDAQ:ANAB · every price before a split is adjusted for it

DayRatioWhat
3-for-2Split
Ticker
NASDAQ:ANAB
Asset type
Stock
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All AnaptysBio, Inc. news

AnaptysBio, Inc. on 6ix

News releases
19 in the last 12 months · 122 in all · newest Nov 12, 2026 · oldest 2019
Decks
30 decks · latest September 2026

Where AnaptysBio, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:ANAB · Home listing · This pageNASDAQUnited StatesUSD
gettex:AN6gettexGermanyEUR
Lang & Schwarz:A2AJ8CLang & SchwarzGermanyEUR
LS Exchange:A2AJ8CLS ExchangeGermanyEUR
BMV:ANABBMVMexicoMXN
LSE:0HFQLSEUnited KingdomUSD
Tradegate:AN6TradegateGermanyEUR
BOATS:ANABBOATSUnited StatesUSD
BIVA:ANABBIVAMexicoMXN
Frankfurt:AN6FrankfurtGermanyEUR
Dusseldorf:AN6DusseldorfGermanyEUR
Munich:AN6MunichGermanyEUR
Stuttgart:AN6StuttgartGermanyEUR

Valuation

Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$1.25B USD
P/E
7.6×
EV/sales
6.5×
EV/EBITDA
6.2×
Price/book
67.0×
Gross margin
143.7%
Operating margin
105.8%
Net margin
96.3%
Debt to equity
0.6×
Beta vs S&P 500
0.95

Forecasts

5 strong buy · 3 buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
87.25 USD · Analysts' mean
EPS, year to Dec 2026
3.24 · 3 analysts
Revenue, year to Dec 2026
136.7M · 1 analyst

Team and board

Officers

OfficerRole
Dan FagaPresident, CEO, and Director
Hollings RentonChair of the Nominating and Corporate Governance Committee
John OrwinBoard Chairman of First Tracks Bio Former CEO of Relypsa
Christopher MurphyCFO
Nick MontemaranoExecutive Director, Investor Relations

Board

DirectorRole
John OrwinBoard Chairman of First Tracks Bio Former CEO of Relypsa
Dan FagaPresident, CEO, and Director
Hollings RentonChair of the Nominating and Corporate Governance Committee
Nick MontemaranoExecutive Director, Investor Relations
Oleg NodelmanMember of the Nominating and Corporate Governance Committee
Owen HughesMember of the Audit Committee
Susannah GrayMember of the Audit Committee

Events

QuarterResultsShare move
Q3 2026Nov 12, 2026 · After close−3.2%
Q2 2026Sep 21, 2026 · After close−1.8%
Q1 2026May 7, 2026+2.9%
Q4 2025Mar 3, 2026 · After close+14.6%
Q3 2025Nov 4, 2025 · After close+3.6%
Q2 2025Aug 6, 2025 · After close−9.6%
Q1 2025May 5, 2025 · After close−2.9%
Q4 2024Mar 10, 2025 · Before open+2.4%
Q3 2024Nov 5, 2024 · After close+11.7%
Q2 2024Aug 5, 2024 · After close−0.9%
All 20 quarters
QuarterResultsShare move
Q1 2024May 9, 2024 · After close−10.8%
Q4 2023Mar 11, 2024 · After close+11.6%
Q3 2023Nov 2, 2023 · After close+8.2%
Q2 2023Aug 7, 2023 · After close+2.6%
Q1 2023May 11, 2023 · After close−6.3%
Q4 2022Mar 1, 2023 · After close−2.4%
Q3 2022Nov 8, 2022 · After close−0.9%
Q2 2022Aug 8, 2022 · After close−5.6%
Q1 2022May 4, 2022 · After close−11.1%
Q4 2021Mar 7, 2022 · Before open−0.8%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (September 2026)Investor deck10 slidesSeptember 2026
Investor Presentation (March 2026)Investor deck66 slidesMar 3, 2026
Investor Presentation (January 2026)Investor deck65 slidesJan 9, 2026
Investor Presentation (November 2025)Investor deck67 slidesNov 10, 2025
Investor Day (October 2025)Investor day56 slidesOct 14, 2025
Investor Presentation (October 2025)Investor deck72 slidesOct 14, 2025
Merger or Acquisition (September 2025)Merger or acquisition13 slidesSep 29, 2025
Investor Presentation (June 2025)Investor deck55 slidesJun 3, 2025
Technical Presentation (June 2025)Technical38 slidesJun 3, 2025
Investor Presentation (February 2025)Investor deck45 slidesFeb 19, 2025
All 30 decks
DeckKindSlidesDate
Technical Presentation (February 2025)Technical20 slidesFeb 12, 2025
ACR Convergence 2025Conference20 slides2025
Technical Presentation (2025)Technical11 slides2025
Technical Presentation (May 2024)Technical4 slidesMay 2024
Technical Presentation (March 2024)Technical4 slidesMarch 2024
Investor Presentation (January 2024)Investor deck51 slidesJan 5, 2024
Technical Presentation (2024)Technical13 slides2024
Technical Presentation (October 2023)Technical71 slidesOct 25, 2023
Investor Presentation (January 2023)Investor deck47 slidesJan 5, 2023
Technical Presentation (2023)Technical12 slides2023
Investor Presentation (November 2022)Investor deck33 slidesNov 8, 2022
Investor Presentation (September 2022)Investor deck24 slidesSep 12, 2022
Jefferies Virtual Healthcare Conference 2021Conference33 slidesJun 3, 2021
39th Annual J.P. Morgan Healthcare Conference 2021Conference35 slidesJan 11, 2021
Festival of Biologics 2020Conference16 slidesMar 2, 2020
J.P. Morgan 38th Annual Healthcare Conference (January 2020)Conference34 slidesJan 15, 2020
Technical Presentation (September 2018)Technical15 slidesSep 24, 2018
Technical Presentation (March 2018)Technical16 slidesMar 26, 2018
American Academy of Dermatology Annual Meeting 2018Conference10 slidesFeb 17, 2018
Technical Presentation (March 2017)Technical14 slidesMarch 2017

Open Decks

IPO

Priced at US$15.00 a share on Jan 25, 2017.

Price
US$15.00 a share
Shares offered
5,000,000 shares of common stock
Offering size
US$75 million
Underwriters' option
Up to 750,000 more shares
Underwriters
Credit Suisse, Stifel, JMP Securities, Wedbush PacGrow · In the order on the cover
Shares delivered
On or about Jan 31, 2017

Steps

StepWhen
Draft sent to the SEC in confidenceJul 17, 2015
Filed publiclySep 9, 2015
Amended 7 timesNewest Jan 17, 2017
Shares registered with an exchangeJan 17, 2017
Declared effective by the SECJan 25, 2017
Final prospectus, with the priceJan 26, 2017

Open IPO · From the cover of the final prospectus (424B4) filed Jan 26, 2017

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue234.6M91.3M17.2M10.3M63.2M75.0M8.00M5.00M10.0M16.7M
Cost of revenue2.42M163.8M132.3M88.8M98.5M80.0M99.3M56.2M29.4M15.4M
Gross profit232.2M-72.6M-115.1M-78.5M-35.3M-5.03M-91.3M-51.2M-19.4M1.26M
Research and development136.0M163.8M132.3M88.8M98.5M80.0M99.3M56.2M29.4M15.4M
Selling, general and administrative50.7M42.4M41.9M36.6M21.5M18.9M16.1M15.5M9.34M4.29M
Operating income226.9M66.2M-164.4M-115.2M-56.8M-23.9M-107.4M-66.7M-28.8M-3.02M
Depreciation and amortization20.0K20.0K652.0K675.0K619.0K559.0K514.0K315.0K183.0K233.0K
EBITDA226.9M66.2M-163.8M-114.5M-56.2M-23.3M-106.9M-66.4M-28.6M-2.79M
Interest expense79.9M50.1M18.1M21.1M001.04M1.65M1.77M458.0K
Income before tax162.3M31.1M-163.6M-128.7M-57.8M-19.9M-97.5M-61.8M-30.1M-4.26M
Income tax772.0K158.0K-4.00K24.0K00-152.0K-192.0K00
Net income-13.2M-145.2M-163.6M-128.7M-57.8M-19.9M-97.3M-61.7M-30.1M-4.26M
Earnings per share, basic-0.46-5.12-6.08-4.57-2.11-0.73-3.60-2.50-1.52-1.62
Earnings per share, diluted-0.44-4.92-6.08-4.57-2.11-0.73-3.60-2.50-1.52-1.62

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents138.2M23.1M36.0M71.3M495.7M250.5M171.0M113.6M81.2M51.2M
Short-term investments73.4M262.3M354.9M369.9M52.4M143.2M203.2M313.5M167.2M0
Receivables33.9M40.8M6.85M1.42M876.0K00001.23M
Inventory11101
Current assets350.3M431.9M406.8M447.2M553.9M396.6M377.7M434.2M252.7M58.2M
Property, plant and equipment111.0K131.0K2.10M2.09M2.28M1.78M1.62M1.45M665.0K471.0K
Goodwill0
Total assets364.4M483.8M452.4M610.4M643.1M416.6M435.2M509.0M329.4M62.2M
Accounts payable3.87M4.00M4.70M2.78M1.74M4.22M16.2M5.44M2.32M2.28M
Current liabilities38.6M45.4M37.4M26.1M16.1M19.8M29.5M21.8M14.1M5.71M
Long-term debt625.0K7.55M13.8M
Total debt14.1M369.5M17.8M19.4M21.0M342.0K2.90M8.26M14.4M13.8M
Total liabilities327.2M413.0M364.3M348.3M286.6M19.8M30.2M22.6M21.8M22.9M
Shareholders' equity37.2M70.9M88.1M262.1M356.4M396.7M405.0M486.4M307.6M-38.2M
Shares outstanding28.0M30.5M26.6M28.5M27.6M27.4M27.3M26.9M23.8M2.65M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations19.7M-135.3M-120.8M-73.6M-45.9M-14.2M-69.5M-48.5M-19.4M-9.03M
Capital spending-87.0K-358.0K-807.0K-358.0K-1.37M-569.0K-805.0K-1.06M-290.0K-50.0K
Free cash flow19.6M-135.7M-121.6M-74.0M-47.3M-14.7M-70.3M-49.6M-19.7M-9.08M
Cash from investing228.0M31.4M144.8M-394.8M38.8M94.5M131.4M-142.5M-243.1M-50.0K
Cash from financing-132.6M127.1M-59.3M44.0M252.3M-879.0K-4.49M223.4M292.5M8.63M
Dividends paid-11.7M0
Share buybacks-68.6M-456.0K-50.0M00496.0K3.01M00-1.00K
Change in cash115.1M23.1M-35.3M-424.4M245.2M79.4M57.4M32.4M30.0M-452.0K

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13D/A · Big-stake notice, amendedNov 18, 2026Big-stake noticeSEC
4 · Change in ownershipNov 18, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 12, 2026Quarterly reportSEC
8-K · Current reportNov 12, 2026ResultsSEC
4 · Change in ownershipOct 2, 2026Insider tradeSEC
144 · Notice of proposed saleOct 1, 2026Other filingsSEC
10-KT · Transition reportSep 21, 2026Annual reportSEC
8-K · Current reportSep 21, 2026Current reportSEC
4 · Change in ownershipSep 17, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
8-K · Current reportAug 11, 2026Meeting outcomeSEC
4 · Change in ownershipAug 7, 2026Insider tradeSEC
4 · Change in ownershipAug 7, 2026Insider tradeSEC
8-K · Current reportJul 30, 2026Current reportSEC
144 · Notice of proposed saleJul 13, 2026Other filingsSEC
144 · Notice of proposed saleJun 30, 2026Other filingsSEC
144 · Notice of proposed saleJun 29, 2026Other filingsSEC
ARS · Annual report to shareholdersJun 29, 2026Annual reportSEC
DEFA14A · Additional proxy materialJun 29, 2026Meeting noticeSEC
DEF 14A · Proxy statementJun 29, 2026Meeting noticeSEC
144 · Notice of proposed saleJun 26, 2026Other filingsSEC
8-K · Current reportJun 22, 2026Material contractSEC
144 · Notice of proposed saleJun 17, 2026Other filingsSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
144 · Notice of proposed saleJun 16, 2026Other filingsSEC
144 · Notice of proposed saleJun 15, 2026Other filingsSEC
144 · Notice of proposed saleJun 12, 2026Other filingsSEC
144 · Notice of proposed saleJun 11, 2026Other filingsSEC
144 · Notice of proposed saleJun 10, 2026Other filingsSEC
144 · Notice of proposed saleJun 9, 2026Other filingsSEC
144 · Notice of proposed saleJun 8, 2026Other filingsSEC
144 · Notice of proposed saleJun 5, 2026Other filingsSEC
144 · Notice of proposed saleJun 5, 2026Other filingsSEC
144 · Notice of proposed saleJun 3, 2026Other filingsSEC
144 · Notice of proposed saleJun 2, 2026Other filingsSEC
144 · Notice of proposed saleJun 1, 2026Other filingsSEC
8-K · Current reportMay 29, 2026Current reportSEC
144 · Notice of proposed saleMay 29, 2026Other filingsSEC
144 · Notice of proposed saleMay 28, 2026Other filingsSEC
144 · Notice of proposed saleMay 27, 2026Other filingsSEC
144 · Notice of proposed saleMay 26, 2026Other filingsSEC
144 · Notice of proposed saleMay 22, 2026Other filingsSEC
8-K · Current reportMay 21, 2026Current reportSEC
144 · Notice of proposed saleMay 21, 2026Other filingsSEC
144 · Notice of proposed saleMay 19, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
144 · Notice of proposed saleMay 15, 2026Other filingsSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2026Big-stake noticeSEC
4 · Change in ownershipMay 13, 2026Insider tradeSEC
3 · Initial statement of ownershipMay 13, 2026Insider tradeSEC
4 · Change in ownershipMay 13, 2026Insider tradeSEC
3 · Initial statement of ownershipMay 13, 2026Insider tradeSEC
10-Q · Quarterly reportMay 12, 2026Quarterly reportSEC
8-K · Current reportMay 12, 2026ResultsSEC
8-K · Current reportMay 11, 2026Management or board changeSEC
4 · Change in ownershipApr 29, 2026Insider tradeSEC
10-K/A · Annual report, amendedApr 28, 2026Annual reportSEC
8-K/A · Current report, amendedApr 24, 2026Current reportSEC
4/A · Change in ownership, amendedApr 23, 2026Insider tradeSEC
4 · Change in ownershipApr 22, 2026Insider tradeSEC
4 · Change in ownershipApr 22, 2026Insider tradeSEC
4 · Change in ownershipApr 22, 2026Insider tradeSEC
4 · Change in ownershipApr 22, 2026Insider tradeSEC
4 · Change in ownershipApr 22, 2026Insider tradeSEC
8-K · Current reportApr 20, 2026Acquisition or disposalSEC
3 · Initial statement of ownershipApr 3, 2026Insider tradeSEC
4 · Change in ownershipApr 1, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 1, 2026Insider tradeSEC
144 · Notice of proposed saleMar 30, 2026Other filingsSEC
4 · Change in ownershipMar 27, 2026Insider tradeSEC
8-K · Current reportMar 27, 2026Material contractSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 26, 2026Big-stake noticeSEC
10-K · Annual reportMar 3, 2026Annual reportSEC
8-K · Current reportMar 3, 2026ResultsSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 11, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 11, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 16, 2026Big-stake noticeSEC
4 · Change in ownershipJan 16, 2026Insider tradeSEC
144 · Notice of proposed saleJan 15, 2026Other filingsSEC
4 · Change in ownershipJan 9, 2026Insider tradeSEC
144 · Notice of proposed saleJan 9, 2026Other filingsSEC
4 · Change in ownershipJan 9, 2026Insider tradeSEC
144 · Notice of proposed saleJan 9, 2026Other filingsSEC
4 · Change in ownershipJan 9, 2026Insider tradeSEC
144 · Notice of proposed saleJan 9, 2026Other filingsSEC
4 · Change in ownershipJan 9, 2026Insider tradeSEC
144 · Notice of proposed saleJan 9, 2026Other filingsSEC
8-K · Current reportJan 9, 2026ResultsSEC
4 · Change in ownershipJan 8, 2026Insider tradeSEC
144 · Notice of proposed saleJan 8, 2026Other filingsSEC
4 · Change in ownershipJan 8, 2026Insider tradeSEC
144 · Notice of proposed saleJan 8, 2026Other filingsSEC
4 · Change in ownershipJan 8, 2026Insider tradeSEC
144 · Notice of proposed saleJan 8, 2026Other filingsSEC
4 · Change in ownershipJan 8, 2026Insider tradeSEC
144 · Notice of proposed saleJan 8, 2026Other filingsSEC
4 · Change in ownershipJan 8, 2026Insider tradeSEC
4 · Change in ownershipJan 8, 2026Insider tradeSEC
4 · Change in ownershipJan 8, 2026Insider tradeSEC
4 · Change in ownershipJan 8, 2026Insider tradeSEC
4 · Change in ownershipJan 8, 2026Insider tradeSEC
4 · Change in ownershipJan 8, 2026Insider tradeSEC
4 · Change in ownershipJan 8, 2026Insider tradeSEC
144 · Notice of proposed saleJan 7, 2026Other filingsSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
144 · Notice of proposed saleJan 6, 2026Other filingsSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
144 · Notice of proposed saleJan 6, 2026Other filingsSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
144 · Notice of proposed saleJan 6, 2026Other filingsSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
144 · Notice of proposed saleJan 6, 2026Other filingsSEC
4 · Change in ownershipDec 23, 2025Insider tradeSEC
4 · Change in ownershipDec 23, 2025Insider tradeSEC
4 · Change in ownershipDec 23, 2025Insider tradeSEC
4 · Change in ownershipDec 23, 2025Insider tradeSEC
4 · Change in ownershipDec 23, 2025Insider tradeSEC
144 · Notice of proposed saleDec 23, 2025Other filingsSEC
144 · Notice of proposed saleDec 22, 2025Other filingsSEC
144 · Notice of proposed saleDec 22, 2025Other filingsSEC
144 · Notice of proposed saleDec 22, 2025Other filingsSEC
4 · Change in ownershipDec 18, 2025Insider tradeSEC
4 · Change in ownershipDec 18, 2025Insider tradeSEC
144 · Notice of proposed saleDec 18, 2025Other filingsSEC
144 · Notice of proposed saleDec 17, 2025Other filingsSEC
144 · Notice of proposed saleDec 16, 2025Other filingsSEC
144 · Notice of proposed saleDec 16, 2025Other filingsSEC
8-K · Current reportNov 26, 2025Current reportSEC
8-K · Current reportNov 21, 2025Current reportSEC
8-K · Current reportNov 21, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 12, 2025Big-stake noticeSEC
8-K · Current reportNov 10, 2025Current reportSEC
10-Q · Quarterly reportNov 4, 2025Quarterly reportSEC
8-K · Current reportNov 4, 2025ResultsSEC
8-K · Current reportOct 14, 2025Current reportSEC
4 · Change in ownershipOct 1, 2025Insider tradeSEC
144 · Notice of proposed saleSep 30, 2025Other filingsSEC
8-K · Current reportSep 29, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeSep 23, 2025Big-stake noticeSEC
4 · Change in ownershipSep 17, 2025Insider tradeSEC
4 · Change in ownershipAug 12, 2025Insider tradeSEC
144 · Notice of proposed saleAug 8, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 7, 2025Big-stake noticeSEC
S-8 · Registration statement for employee plansAug 6, 2025Offer documentSEC
10-Q · Quarterly reportAug 6, 2025Quarterly reportSEC
8-K · Current reportAug 6, 2025ResultsSEC
SCHEDULE 13G · Big-stake noticeAug 5, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJul 29, 2025Big-stake noticeSEC
4 · Change in ownershipJul 3, 2025Insider tradeSEC
144 · Notice of proposed saleJul 2, 2025Other filingsSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
144 · Notice of proposed saleJun 18, 2025Other filingsSEC
144 · Notice of proposed saleJun 18, 2025Other filingsSEC
4 · Change in ownershipJun 17, 2025Insider tradeSEC
4 · Change in ownershipJun 17, 2025Insider tradeSEC
4 · Change in ownershipJun 17, 2025Insider tradeSEC
4 · Change in ownershipJun 17, 2025Insider tradeSEC
4 · Change in ownershipJun 17, 2025Insider tradeSEC
4 · Change in ownershipJun 17, 2025Insider tradeSEC
4 · Change in ownershipJun 17, 2025Insider tradeSEC
8-K · Current reportJun 17, 2025Meeting outcomeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJun 6, 2025Big-stake noticeSEC
8-K · Current reportJun 3, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 12, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 12, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 5, 2025Quarterly reportSEC
8-K · Current reportMay 5, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 30, 2025Big-stake noticeSEC
ARS · Annual report to shareholdersApr 29, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 29, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 29, 2025Meeting noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 17, 2025Big-stake noticeSEC
4 · Change in ownershipMar 27, 2025Insider tradeSEC
8-K · Current reportMar 24, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeMar 7, 2025Big-stake noticeSEC
10-K · Annual reportFeb 27, 2025Annual reportSEC
8-K · Current reportFeb 27, 2025ResultsSEC
8-K · Current reportFeb 19, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeFeb 18, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
8-K · Current reportFeb 12, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 5, 2025Big-stake noticeSEC
8-K · Current reportFeb 3, 2025Material contractSEC
4 · Change in ownershipJan 15, 2025Insider tradeSEC
4 · Change in ownershipJan 7, 2025Insider tradeSEC
4 · Change in ownershipJan 7, 2025Insider tradeSEC
4 · Change in ownershipJan 7, 2025Insider tradeSEC
4 · Change in ownershipJan 7, 2025Insider tradeSEC
4 · Change in ownershipJan 7, 2025Insider tradeSEC
4 · Change in ownershipJan 7, 2025Insider tradeSEC
4 · Change in ownershipJan 7, 2025Insider tradeSEC

This page holds 200 of 730 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from AnaptysBio, Inc.’s releases · as of Sep 21, 2026

Common shares
29,895,244
Fully diluted
29,895,244

Fully diluted

LineSharesAs of
Common shares29,895,244Sep 21, 2026

Share count over time

CountShares
Sep 21, 202629,895,244

Open Cap table

Shareholders

Institutions

HolderSharesValueAs of
EcoR1 Capital, LLC7.88MUS$396MSep 30, 2026
BlackRock1.89MUS$95.1MSep 30, 2026
Tang Capital Management LLC1.47MUS$74.1MSep 30, 2026
Vanguard1.46MUS$73.5MSep 30, 2026
State Street1.15MUS$57.6MSep 30, 2026
Goldman Sachs850KUS$42.7MSep 30, 2026
Sanofi822KUS$41.3MSep 30, 2026
D. E. Shaw & Co., Inc.820KUS$41.2MSep 30, 2026
Millennium785KUS$39.4MSep 30, 2026
683 Capital Management, LLC740KUS$37.2MSep 30, 2026
Show 50 holders
HolderSharesValueAs of
Citadel651KUS$32.7MSep 30, 2026
Geode Capital640KUS$32.2MSep 30, 2026
Palo Alto Investors LP595KUS$29.9MSep 30, 2026
Pertento Partners LLP545KUS$27.4MSep 30, 2026
Arrowstreet Capital, Limited Partnership496KUS$24.9MSep 30, 2026
Federated Hermes, Inc.468KUS$23.5MSep 30, 2026
Apis Capital Advisors, LLC444KUS$22.3MSep 30, 2026
Morgan Stanley404KUS$20.3MSep 30, 2026
Jacobs Levy Equity Management, Inc353KUS$17.7MSep 30, 2026
Bank of America339KUS$17MSep 30, 2026
Nuveen335KUS$16.8MSep 30, 2026
Sofinnova Investments, Inc.330KUS$16.6MSep 30, 2026
First Light Asset Management, LLC329KUS$16.5MSep 30, 2026
Two Sigma304KUS$15.3MSep 30, 2026
Irenic Capital Management LP299KUS$15MSep 30, 2026
Invesco251KUS$12.6MSep 30, 2026
Qube Research & Technologies Ltd232KUS$11.7MSep 30, 2026
First Trust231KUS$11.6MSep 30, 2026
Schwab217KUS$10.9MSep 30, 2026
HSBC210KUS$10.7MSep 30, 2026
Northern Trust205KUS$10.3MSep 30, 2026
Dimensional198KUS$9.95MSep 30, 2026
Mackenzie187KUS$9.38MSep 30, 2026
Crcm LP181KUS$9.1MSep 30, 2026
Diamond Hill Capital Management, LLC (Investment Advisor)170KUS$8.55MSep 30, 2026
T. Rowe Price169KUS$8.51MSep 30, 2026
Victory Capital166KUS$8.33MSep 30, 2026
UBS163KUS$8.21MSep 30, 2026
Eversept Partners, LP155KUS$7.79MSep 30, 2026
Greenhaven Road Investment Management, L.P.146KUS$7.32MSep 30, 2026
Schonfeld Strategic Advisors LLC111KUS$5.57MSep 30, 2026
Squarepoint Ops LLC110KUS$5.51MSep 30, 2026
Ruffer LLP107KUS$5.36MSep 30, 2026
Principal102KUS$5.11MSep 30, 2026
Connor, Clark & Lunn Investment Management Ltd.94,037US$4.73MSep 30, 2026
Nomura93,732US$4.71MSep 30, 2026
Ensign Peak Advisors, Inc89,512US$4.5MSep 30, 2026
Capital Fund Management S.A.85,871US$4.32MSep 30, 2026
Russell Investments Group, Ltd.84,859US$4.27MSep 30, 2026
Moody Aldrich Partners LLC81,688US$4.11MSep 30, 2026

This page holds 50 of 221 holders. Open Shareholders

Funds

HolderSharesValueAs of
State Street(R) SPDR(R) S&P(R) Biotech ETF787KUS$53.1MJun 30, 2026
Vanguard Total Stock Market Index Fund648KUS$43.7MJun 30, 2026
iShares Russell 2000 ETF515KUS$34.8MJun 30, 2026
Nuveen Quant Small Cap Equity Fund264KUS$14.1MJul 31, 2026
Vanguard Extended Market Index Fund237KUS$16MJun 30, 2026
Fidelity Small Cap Index Fund216KUS$11.5MJul 31, 2026
Federated Hermes Kaufmann Small Cap Fund210KUS$11.2MJul 31, 2026
iShares Biotechnology ETF194KUS$13.1MJun 30, 2026
Victory Science & Technology Fund188KUS$10MJul 31, 2026
iShares Russell 2000 Growth ETF186KUS$12.5MJun 30, 2026
Show 50 holders
HolderSharesValueAs of
Burney U.S. Equity Select ETF143KUS$7.95MJul 31, 2026
Vanguard Strategic Equity Fund131KUS$8.86MJun 30, 2026
First Trust Small Cap Growth AlphaDEX Fund130KUS$6.94MJul 31, 2026
Federated Hermes MDT Small Cap Core Fund128KUS$6.81MJul 31, 2026
Invesco Biotechnology & Genome ETF121KUS$6.47MJul 31, 2026
Burney U.S. Factor Rotation ETF119KUS$6.61MJul 31, 2026
Vanguard Explorer Fund112KUS$6MJul 31, 2026
Fidelity Extended Market Index Fund102KUS$5.66MMay 31, 2026
Schwab U.S. Small-Cap ETF94,549US$5.26MMay 31, 2026
Nomura Healthcare Fund93,732US$6.33MJun 30, 2026
Vanguard Russell 2000 Index Fund93,704US$5.22MMay 31, 2026
U.S. Small Cap Portfolio70,627US$3.77MJul 31, 2026
First Trust Small Cap Core AlphaDEX Fund64,617US$3.45MJul 31, 2026
Dimensional U.S. Small Cap ETF64,608US$3.45MJul 31, 2026
Fidelity SAI Small-Mid Cap Momentum Index Fund60,059US$3.2MJul 31, 2026
VictoryShares US Small Mid Cap Value Momentum ETF50,185US$3.39MJun 30, 2026
Victory RS Science & Technology Fund48,060US$3.24MJun 30, 2026
Schwab Small-Cap Index Fund47,930US$2.56MJul 31, 2026
Goldman Sachs Small Cap Equity Insights Fund46,070US$2.46MJul 31, 2026
Fidelity Small-Mid Multifactor ETF44,946US$2.4MJul 31, 2026
Federated Hermes MDT Small Cap Growth Fund44,928US$2.4MJul 31, 2026
College Retirement Equities Fund - Total Global Stock Account43,899US$2.96MJun 30, 2026
Vanguard Health Care Index Fund41,800US$2.33MMay 31, 2026
Vanguard U.S. Momentum Factor ETF40,785US$2.27MMay 31, 2026
Fidelity Total Market Index Fund37,064US$2.06MMay 31, 2026
Master Small Cap Index Series36,931US$2.49MJun 30, 2026
Victory RS Small Cap Growth Fund35,700US$2.41MJun 30, 2026
Invesco BuyBack AchieversTM ETF31,971US$1.71MJul 31, 2026
Victory Small Cap Stock Fund31,643US$1.69MJul 31, 2026
Vanguard Strategic Small-Cap Equity Fund31,285US$2.11MJun 30, 2026
Tema Oncology ETF31,270US$1.74MMay 31, 2026
Fidelity Series Total Market Index Fund29,860US$1.66MMay 31, 2026
iShares Core S&P Total U.S. Stock Market ETF29,157US$1.97MJun 30, 2026
Nuveen Quant Small/Mid Cap Equity Fund28,500US$1.52MJul 31, 2026
Direxion Daily S&P Biotech Bull 3X Shares26,728US$1.43MJul 31, 2026
JPMorgan U.S. Small Company Fund26,597US$1.8MJun 30, 2026
Nuveen Small Cap Blend Index Fund26,172US$1.4MJul 31, 2026
U.S. Micro Cap Portfolio23,992US$1.28MJul 31, 2026
Select Biotechnology Portfolio23,300US$1.3MMay 31, 2026
EQ/2000 Managed Volatility Portfolio21,453US$1.45MJun 30, 2026

This page holds 50 of 219 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
EcoR1 Capital, LLC
Director, 10% owner
Buy138,093USD 46.54US$6.43MNov 18, 2026
EcoR1 Capital, LLC
Director, 10% owner
Buy152,367USD 45.66US$6.96MNov 17, 2026
EcoR1 Capital, LLC
Director, 10% owner
Buy84,120USD 45.66US$3.84MNov 16, 2026
Renton Hollings
Director
Sale5,000USD 49.87US$249KOct 1, 2026
Schmid John P.
Director
Sale12,596USD 55.71US$702KMar 30, 2026
Schmid John P.
Director
Sale7,527USD 56.70US$427KMar 30, 2026
Schmid John P.
Director
Sale522USD 57.40US$29,963Mar 30, 2026

Big stakes

StakeStakeSharesDateFiling
EcoR1 Capital, LLC27.80%8.25MNov 16, 2026Schedule 13D
BlackRock, Inc.6.20%1.9MMar 31, 2025Schedule 13G
James N. Topper5.40%1.66MDec 31, 2024Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
James N Topper
Other companies: Attovia Therapeutics, Inc. (Director · Since at least Aug 4, 2026); NewAmsterdam Pharma Company N.V. (Director · Since at least Dec 29, 2023); Phathom Pharmaceuticals, Inc. (Director · Since at least Oct 24, 2019); Frazier Lifesciences Acquisition Corp (Chief Executive Officer, Director · Dec 8, 2020 – Dec 11, 2020 · Past); Entasis Therapeutics Holdings Inc (Director · Sep 25, 2018 – Jan 18, 2019 · Past); Aptinyx Inc (Director · Jun 20, 2018 – Mar 31, 2020 · Past); Allena Pharmaceuticals Inc (Director · Nov 1, 2017 – Nov 17, 2020 · Past); Alpine Immune Sciences Inc (Director · Jul 24, 2017 – May 18, 2024 · Past); Sierra Oncology Inc (Director · Jul 15, 2015 – Feb 14, 2017 · Past); Portola Pharmaceuticals Inc (Director · May 21, 2013 – Jun 5, 2013 · Past); Amicus Therapeutics Inc (Director · Jun 15, 2010 – Jun 12, 2014 · Past)
Director · Jan 25, 2017 – Jan 6, 2023 · Past
John Schmid
Other companies: BlossomHill Therapeutics, Inc. (Director · Since at least Aug 6, 2026); First Tracks Biotherapeutics, Inc. (Director · Since at least Apr 1, 2026); Helix Acquisition Corp. III (Director · Since at least Jan 22, 2026); Design Therapeutics, Inc. (Director · Since at least Mar 25, 2021); BridgeBio Oncology Therapeutics, Inc. (Director · Feb 8, 2024 – Feb 8, 2024 · Past); Xeris Biopharma Holdings, Inc. (Director · Oct 5, 2021 – Aug 12, 2024 · Past); MoonLake Immunotherapeutics (Director · Oct 19, 2020 – Oct 19, 2020 · Past); Poseida Therapeutics Inc (Director · Jul 9, 2020 – Jan 8, 2025 · Past); Neos Therapeutics Inc (Director · Jul 2, 2018 – Mar 19, 2021 · Past)
Director · Since at least Feb 2, 2018
Hollings Renton
Other companies: Zymeworks Inc. (Director · Jan 1, 2019 – Dec 7, 2023 · Past); Kythera Biopharmaceuticals Inc (Director · Dec 31, 2014 – Oct 1, 2015 · Past); Portola Pharmaceuticals Inc (Director · May 21, 2013 – Jul 2, 2020 · Past); Affymax Inc (Director · Jun 9, 2009 – Jun 13, 2012 · Past); Rigel Pharmaceuticals, Inc. (Director · May 31, 2006 – May 15, 2013 · Past); Cepheid (Director · Apr 27, 2006 – Nov 4, 2016 · Past); Onyx Pharmaceuticals Inc (President and CEO, Director · Jan 19, 2006 – Feb 19, 2008 · Past)
Chair of the Nominating and Corporate Governance Committee · Since at least Jan 25, 2017
Oleg Nodelman
Other companies: Theravance Biopharma, Inc. (BSFS · Since at least Nov 5, 2026); Aktis Oncology, Inc. (Director · Since at least Jan 8, 2026); Zymeworks Inc. (Director · Since at least Feb 17, 2025); Nuvation Bio Inc. (Director · Jun 30, 2020 – Sep 19, 2023 · Past); Panacea Acquisition II Corp (Director · Apr 6, 2020 – Apr 28, 2023 · Past); Prothena Corporation plc (Director · Dec 3, 2019 – Dec 3, 2019 · Past); Kindred Biosciences Inc (Director · Dec 11, 2013 – Sep 29, 2014 · Past)
Member of the Nominating and Corporate Governance Committee · Since at least Apr 8, 2021
Owen Hughes
Other companies: XOMA Royalty Corporation (Chief Executive Officer, Director · Since at least Nov 11, 2024); C4 Therapeutics, Inc. (Director · Since at least Nov 16, 2023); ImageneBio, Inc. (Director · Dec 14, 2022 – Jun 7, 2024 · Past); Pardes Biosciences Inc (Director · Feb 16, 2021 – Dec 23, 2021 · Past); Cullinan Therapeutics, Inc. (President and CEO, Director · Jan 7, 2021 – Jan 12, 2021 · Past); Translate Bio Inc (Director · Jun 27, 2018 – Sep 14, 2021 · Past); Radius Health, Inc. (Director · Apr 23, 2013 – Aug 15, 2022 · Past)
Member of the Audit Committee · Since at least May 11, 2026
Dennis M Fenton
Other companies: First Tracks Biotherapeutics, Inc. (Director · Since at least Apr 1, 2026); Portola Pharmaceuticals Inc (Director · Jun 17, 2016 – Jul 2, 2020 · Past); XenoPort Inc (Director · May 17, 2016 – Jul 5, 2016 · Past); Pfenex Inc (Director · May 6, 2016 – May 5, 2017 · Past)
Director · Since at least Mar 5, 2018
Rita Jain
Other companies: First Tracks Biotherapeutics, Inc. (Director · Since at least Apr 1, 2026); SAB Biotherapeutics, Inc. (Director · Since at least Jan 5, 2026); Avalo Therapeutics, Inc. (Director · Since at least Jun 17, 2025); Celldex Therapeutics, Inc. (Director · Since at least Jun 13, 2024)
Director · Since at least Jan 3, 2024
Susannah Gray
Other companies: Maravai LifeSciences Holdings, Inc. (Director · Since at least May 23, 2024); 4D Molecular Therapeutics, Inc. (Director · Since at least May 21, 2024); Theravance Biopharma, Inc. (Director · Since at least May 8, 2024); Morphic Holding Inc (Director · Jun 4, 2024 – Aug 16, 2024 · Past)
Director · Since at least Mar 26, 2026
J Anthony Ware
Other companies: First Tracks Biotherapeutics, Inc. (Director · Since at least Apr 1, 2026)
Director · Since at least Aug 22, 2017
Nick Montemarano
Other companies: First Tracks Biotherapeutics, Inc. (Vice President, Investor Relations · Since at least Nov 3, 2026)
Executive Director, Investor Relations · Since at least Mar 3, 2026
All 16 people
PersonSeat
Christopher MurphyCFO · Since at least May 11, 2026
Dan FagaPresident, CEO, and Director · Since at least Apr 24, 2026
Eric J LoumeauCHIEF LEGAL OFFICER · Since at least Sep 30, 2025
John OrwinBoard Chairman of First Tracks Bio Former CEO of Relypsa · Since at least Sep 17, 2026
Marco LondeiChief Medical Officer · Jan 25, 2017 – Dec 6, 2019 · Past
Matthew MoyleChief Scientific Officer · Jan 25, 2017 – Feb 24, 2017 · Past

Open People

Log in to ask 6ix AI your own questions about AnaptysBio, Inc.